Arix Bioscience
plc
Update
on Iterum Therapeutics Phase 3 trials
LONDON, 18 September 2018: Arix Bioscience plc
("Arix") (LSE: ARIX), a global healthcare and life science company
supporting medical innovation, is pleased to note that its Group
Business, Iterum Therapeutics plc (“Iterum”) (Nasdaq: ITRM) has
initiated the remaining two of three planned Phase 3 pivotal trials
(SURE 2 and SURE 3) of IV and Oral Sulopenem in Complicated Urinary
Tract and Complicated Intra-abdominal Infections.
Iterum Initiates
SURE 2 and SURE 3 Phase 3 Clinical Trials of IV and Oral Sulopenem
in Complicated Urinary Tract and Complicated Intra-abdominal
Infections
Remaining two of
three planned Phase 3 pivotal trials now underway for Iterum’s lead
antibiotic product candidate sulopenem
Potential to be
first and only oral and IV penem antibiotic available globally
Top-line results
for SURE 2 and SURE 3 expected in the second half of 2019, with new
drug application (NDA) submissions anticipated by the end of
2019
DUBLIN, Ireland and
CHICAGO, September 18, 2018 -- Iterum Therapeutics plc
(Nasdaq: ITRM), a clinical-stage pharmaceutical company developing
antibiotics against multi-drug resistant pathogens, today announced
its initiation of the second and third of three planned Phase 3
clinical trials for sulopenem, Iterum’s lead compound and novel
antibiotic for the treatment of gram-negative, multi-drug resistant
infections.
In the second trial, known as Sulopenem for
Resistant Enterobacteriaceae (SURE) 2, IV sulopenem
followed by oral sulopenem etzadroxil combined with probenecid in a
bilayer tablet (oral sulopenem) will be compared to IV ertapenem
followed by oral ciprofloxacin in adults with complicated urinary
tract infections (cUTI). In the third trial, known as SURE 3, IV
sulopenem followed by oral sulopenem is compared to IV ertapenem
followed by a combination of oral ciprofloxacin and oral
metronidazole in adults with complicated intra-abdominal infections
(cIAI).
Iterum press release available here:
https://www.iterumtx.com/news/press-releases/detail/12/iterum-initiates-sure-2-and-sure-3-phase-3-clinical-trials
ENDS
Enquiries
For more information on Arix, please contact:
Arix Bioscience plc
Charlotte Parry, Head of Investor
Relations
+44 (0)20 7290 1072
charlotte@arixbioscience.com
Optimum Strategic Communications
Mary Clark, Supriya Mathur
+44 (0)203 714 1787
optimum.arix@optimumcomms.com
Burns McClellan (US Media & IR
Enquiries)
Lisa Burns, Nancie Steinberg
+1 212-213-0006
arix@burnsmc.com
About Arix Bioscience plc
Arix Bioscience plc is a global healthcare and life science
company supporting medical innovation. Headquartered in
London and with an office in
New York, Arix Bioscience sources,
finances and builds world class healthcare and life science
businesses addressing medical innovation at all stages of
development. Operations are supported by privileged access to
breakthrough academic science and strategic relationships with
leading research accelerators and global pharmaceutical
companies.
Arix Bioscience plc is listed on the Main Market of the London
Stock Exchange. For further information, please visit
www.arixbioscience.com